These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36930265)

  • 41. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
    Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
    Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
    [No Abstract]   [Full Text] [Related]  

  • 42. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
    Bamias A; Stenzl A; Brown SL; Albiges L; Babjuk M; Birtle A; Briganti A; Burger M; Choudhury A; Colecchia M; De Santis M; Fanti S; Fonteyne V; Gallucci M; Rivas JG; Huddart R; Junker K; Kroeze S; Loriot Y; Merseburger A; Montironi R; Necchi A; Oing C; Oldenburg J; Ost P; Pinkawa M; Ribal MJ; Rouprêt M; Thoeny H; Zilli T; Hoskin P
    Eur Urol; 2023 Oct; 84(4):381-389. PubMed ID: 37217391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NCCN Guidelines Updates: Management of Metastatic Kidney Cancer.
    Jonasch E
    J Natl Compr Canc Netw; 2019 May; 17(5.5):587-589. PubMed ID: 31117033
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP).
    ESMO.
    Ann Oncol; 2001 Aug; 12(8):1057-8. PubMed ID: 11583184
    [No Abstract]   [Full Text] [Related]  

  • 45. Patterns of care analysis for head & neck cancer of unknown primary site: a survey inside the German society of radiation oncology (DEGRO).
    Müller von der Grün J; Bon D; Rödel C; Balermpas P
    Strahlenther Onkol; 2018 Aug; 194(8):750-758. PubMed ID: 29761228
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic and therapeutic management of cancer of an unknown primary.
    Pavlidis N; Briasoulis E; Hainsworth J; Greco FA
    Eur J Cancer; 2003 Sep; 39(14):1990-2005. PubMed ID: 12957453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
    Ljungberg B; Albiges L; Abu-Ghanem Y; Bensalah K; Dabestani S; Fernández-Pello S; Giles RH; Hofmann F; Hora M; Kuczyk MA; Kuusk T; Lam TB; Marconi L; Merseburger AS; Powles T; Staehler M; Tahbaz R; Volpe A; Bex A
    Eur Urol; 2019 May; 75(5):799-810. PubMed ID: 30803729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictors of care for patients with cancer of unknown primary site in three Australian hospitals.
    Tan SYS; O'Neill S; Goldstein D; Ward RL; Daniels B; Vajdic CM
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e512-e520. PubMed ID: 29105289
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Structured diagnostics and therapy of the CUP syndrome].
    Löffler H; Neben K; Krämer A
    Radiologe; 2014 Feb; 54(2):112-6. PubMed ID: 24435157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary.
    Losa F; Iglesias L; Pané M; Sanz J; Nieto B; Fusté V; de la Cruz-Merino L; Concha Á; Balañá C; Matías-Guiu X
    Clin Transl Oncol; 2018 Nov; 20(11):1361-1372. PubMed ID: 29808414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
    Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
    Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site - current status and challenges.
    Müller von der Grün J; Tahtali A; Ghanaati S; Rödel C; Balermpas P
    Radiat Oncol; 2017 May; 12(1):82. PubMed ID: 28486947
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and immune profiling for cancer of unknown primary site.
    Haratani K; Hayashi H; Takahama T; Nakamura Y; Tomida S; Yoshida T; Chiba Y; Sawada T; Sakai K; Fujita Y; Togashi Y; Tanizaki J; Kawakami H; Ito A; Nishio K; Nakagawa K
    J Immunother Cancer; 2019 Sep; 7(1):251. PubMed ID: 31519206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
    Westphalen CB; Federer-Gsponer J; Pauli C; Karapetyan AR; Chalabi N; Durán-Pacheco G; Beringer A; Bochtler T; Cook N; Höglander E; Jin DX; Losa F; Mileshkin L; Moch H; Ross JS; Sokol ES; Tothill RW; Krämer A
    ESMO Open; 2023 Dec; 8(6):102035. PubMed ID: 37922692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. EAU guidelines on renal cell carcinoma: the 2010 update.
    Ljungberg B; Cowan NC; Hanbury DC; Hora M; Kuczyk MA; Merseburger AS; Patard JJ; Mulders PF; Sinescu IC;
    Eur Urol; 2010 Sep; 58(3):398-406. PubMed ID: 20633979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AHNS Series: Do you know your guidelines? Guideline recommendations for head and neck cancer of unknown primary site.
    Eskander A; Ghanem T; Agrawal A;
    Head Neck; 2018 Mar; 40(3):614-621. PubMed ID: 29159978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study.
    Guidi L; Valenza C; Battaiotto E; Trapani D; Ghioni MC; Crimini E; Boscolo Bielo L; Venetis K; Belli C; Bottiglieri L; Gervaso L; Cella CA; Ciardiello D; Spada F; Benini L; Adorisio R; Mane E; Fazio N; Guerini Rocco E; Curigliano G; Zampino MG
    ESMO Open; 2024 Aug; 9(8):103662. PubMed ID: 39111110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Fizazi K; Greco FA; Pavlidis N; Pentheroudakis G;
    Ann Oncol; 2011 Sep; 22 Suppl 6():vi64-8. PubMed ID: 21908507
    [No Abstract]   [Full Text] [Related]  

  • 59. From Biology to Diagnosis and Treatment: The Ariadne's Thread in Cancer of Unknown Primary.
    Mathew BG; Aliyuda F; Taiwo D; Adekeye K; Agada G; Sanchez E; Ghose A; Rassy E; Boussios S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982662
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
    Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.